How a new generation of coronary sinus reducer can significantly expand treatment options for patients with coronary microvascular dysfunction

Sponsored by VahatiCor

Anchorperson: B. Samuels

Spokesperson: W. Wijns

Summary

Discover the latest on managing coronary microvascular dysfunction (CMD) with insights from EuroPCR 2025. This session explores how physiology testing helps identify CMD endotypes in the cathlab and highlights the limitations of ETT for patients experiencing angina or dyspnea at rest. Learn about the A-FLUX coronary sinus reducer: a newly designed device optimised for ease of use and symptom relief. With a mechanism of action based on reducing microvascular resistance, this therapy is emerging as a safe, simple, and effective option. The upcoming SERRA-I feasibility study will further strengthen the clinical evidence for CMD patients with persistent angina or angina-like symptoms.

Learning Objectives

To understand the Reducer therapy mechanism of action for coronary microvascular dysfunction
To know the plans of VahatiCor’s for building clinical evidence in coronary microvascular dysfunction
To understand AFLUX’s design to simplify the procedure and increase response rate
To recognise the importance of diagnosing coronary microvascular dysfunction

Speaker

B. Samuels

Welcome and session objectives